Reported / Citable
Background
This product liability action arises from allegedly contaminated infant formula manufactured by Abbott Laboratories in September 2020. Plaintiffs allege their infant son consumed formula contaminated with Cronobacter sakazakii bacteria, causing severe injuries. The case was filed in April 2023 and had a discovery deadline of September 15, 2025 following two prior extensions.
Plaintiffs sought to compel production of two categories of documents: (1) all environmental monitoring test results from Abbott’s Casa Grande, Arizona facility for the entire period from September 2010 to September 2023, and (2) whole-genome sequencing data for any Cronobacter isolates obtained from the facility. The court had previously limited production to the period June 1, 2018 to August 31, 2022. Plaintiffs simultaneously moved to extend the discovery deadline by two months (later arguing for extension through December 2025), citing what they characterized as Abbott’s discovery obstruction and delays from pending CDC FOIA requests.
The Court’s Holding
The court denied both the motion to compel further discovery responses and the motion to extend the discovery deadline. Applying Federal Rule of Civil Procedure 26(b)(1)’s proportionality requirement, the court found that expanding the document production period to include three additional years of environmental testing data and WGS data from September 2022 forward would be “irrelevant and not proportional to the needs of the case.”
Addressing plaintiffs’ three specific obstruction claims, the court found them unavailing. Rolling document productions, even if piecemeal, constitute normal practice and do not violate discovery rules. Abbott’s use of TIFF format for document production complied with the parties’ stipulated protocol, and plaintiffs’ late complaint about searchability could not justify an extension. While the court noted fairness concerns about Abbott’s two-month delay in providing deposition contact information for Douglas Taylor (the site director), it declined to extend the overall discovery period—instead permitting Taylor’s deposition alone to proceed past the September 15 deadline.
The court also rejected the argument that discovery should extend indefinitely pending CDC responses to FOIA requests, noting plaintiffs’ own dilatory conduct in not filing those requests until January and March 2025, nearly two years into litigation. The court reaffirmed its May 2025 ruling allowing supplemental expert reports if the CDC ultimately produced documents, but would not delay the case indefinitely on hope of future government disclosures.
Key Takeaways
- Proportionality under Rule 26 operates as a meaningful check on discovery scope; a roughly four-year production window was deemed reasonable while broader historical periods were not.
- Rolling document productions complying with stipulated protocols do not constitute discovery abuse or justify deadline extensions, even if produced over time.
- Courts will not indefinitely extend discovery deadlines pending external agency action (here, CDC FOIA responses), particularly when plaintiffs delayed initiating such requests.
- Limited relief for witness deposition access does not mandate wholesale discovery extension; courts can craft narrow exceptions to preserve fairness without reopening entire discovery periods.
Why It Matters
This decision reinforces strict application of proportionality and good-cause standards in product liability discovery disputes. While plaintiffs in contamination cases often face legitimate need for comprehensive historical data, courts will not routinely expand temporal scope or deadlines absent clear justification tied to the case’s actual development. The ruling signals skepticism toward broad historical investigations, particularly when spanning thirteen years (2010–2023) or more.
The opinion also illustrates judicial resistance to the “wait-and-see” discovery model where litigation timelines stretch indefinitely pending third-party disclosures. Plaintiffs seeking critical evidence from outside sources bear responsibility for diligent, timely pursuit; delays in pursuing FOIA requests will not excuse extended discovery deadlines. For defendants in similar cases, the ruling validates rolling productions and format compliance with protocols as defensible discovery practices.